Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) CFO James M. Frates Sells 10,896 Shares

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) CFO James M. Frates sold 10,896 shares of the stock in a transaction dated Monday, March 31st. The shares were sold at an average price of $3.47, for a total value of $37,809.12. Following the transaction, the chief financial officer now directly owns 290,988 shares in the company, valued at approximately $1,009,728.36. This represents a 3.61 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Amylyx Pharmaceuticals Stock Performance

NASDAQ AMLX opened at $3.78 on Thursday. The stock has a market capitalization of $334.92 million, a PE ratio of -0.99 and a beta of -0.51. The stock has a 50-day simple moving average of $3.55 and a 200 day simple moving average of $4.05. Amylyx Pharmaceuticals, Inc. has a twelve month low of $1.58 and a twelve month high of $7.27.

Amylyx Pharmaceuticals (NASDAQ:AMLX) last announced its quarterly earnings data on Tuesday, March 4th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.49) by ($0.06). The firm had revenue of ($0.67) million for the quarter. As a group, equities research analysts forecast that Amylyx Pharmaceuticals, Inc. will post -2.2 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reiterated a “buy” rating and set a $12.00 price target on shares of Amylyx Pharmaceuticals in a report on Wednesday, March 5th. Three equities research analysts have rated the stock with a hold rating, three have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $7.33.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in AMLX. FMR LLC lifted its stake in shares of Amylyx Pharmaceuticals by 292.0% in the third quarter. FMR LLC now owns 221,001 shares of the company’s stock valued at $716,000 after buying an additional 164,622 shares during the period. JPMorgan Chase & Co. raised its holdings in Amylyx Pharmaceuticals by 144.4% in the 3rd quarter. JPMorgan Chase & Co. now owns 140,559 shares of the company’s stock valued at $455,000 after acquiring an additional 83,048 shares in the last quarter. Barclays PLC lifted its position in shares of Amylyx Pharmaceuticals by 91.1% in the 3rd quarter. Barclays PLC now owns 84,572 shares of the company’s stock worth $274,000 after acquiring an additional 40,319 shares during the period. Walleye Capital LLC lifted its position in shares of Amylyx Pharmaceuticals by 986.5% in the 3rd quarter. Walleye Capital LLC now owns 670,594 shares of the company’s stock worth $2,173,000 after acquiring an additional 608,874 shares during the period. Finally, Geode Capital Management LLC grew its holdings in shares of Amylyx Pharmaceuticals by 17.5% during the 3rd quarter. Geode Capital Management LLC now owns 551,039 shares of the company’s stock worth $1,786,000 after purchasing an additional 82,173 shares in the last quarter. Institutional investors own 95.84% of the company’s stock.

Amylyx Pharmaceuticals Company Profile

Amylyx Pharmaceuticals, Inc, a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada.